NCT03762148

Brief Summary

Iron deficiency is still the most common and widespread nutritional disorder in the world according to WHO. In a recent iron absorption study in adult women with low iron stores in our lab (publication under review), we found that 15 g of GOS given with an iron supplement in the form of iron fumarate acutely increased iron absorption when given with water and a bread based meal. The dose of 15 g of GOS was tolerated well by the participants. As a follow up to the study mentioned above, we want to investigate: 1) if acute iron absorption is affected by lower doses of GOS; 2) whether this acute effect occurs for other commonly used iron compounds as well, such as iron sulphate and iron phosphate; and 3) if there are potential interactions on absorption with other enhancers of iron absorption, such as vitamin c.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
46

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Apr 2019

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 30, 2018

Completed
3 days until next milestone

First Posted

Study publicly available on registry

December 3, 2018

Completed
4 months until next milestone

Study Start

First participant enrolled

April 1, 2019

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 11, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 11, 2019

Completed
Last Updated

July 25, 2019

Status Verified

July 1, 2019

Enrollment Period

2 months

First QC Date

November 30, 2018

Last Update Submit

July 24, 2019

Conditions

Keywords

iron-deficiencyprebioticsgalacto-oligosaccharides

Outcome Measures

Primary Outcomes (1)

  • fractional iron absorption

    Fractional iron absorption will be calculated based on the shift of the iron isotope ratios in the collected blood samples after the administration of several isotopically labelled iron supplements.Fractional iron absorption will be measured as erythrocyte incorporation of the naturally occurring iron forms with different masses used to label the iron supplements.

    2 months

Study Arms (9)

ferrous fumarate

EXPERIMENTAL

labelled iron as ferrous fumarate

Dietary Supplement: ferrous fumarate

ferrous sulphate

EXPERIMENTAL

labelled iron as ferrous sulphate

Dietary Supplement: ferrous sulphate

ferric pyrophosphate

EXPERIMENTAL

labelled iron as ferric pyrophosphate

Dietary Supplement: ferric pyrophosphate

ferrous fumarate + 3.5 g GOS

EXPERIMENTAL

labelled iron as ferrous fumarate + prebiotics in the form of 3.5 g GOS

Dietary Supplement: ferrous fumarate + 3.5 g GOS

ferrous fumarate + 7 g GOS

EXPERIMENTAL

labelled iron as ferrous fumarate + prebiotics in the form of 7 g GOS

Dietary Supplement: ferrous fumarate + 7 g GOS

ferrous sulphate + 15 g GOS

EXPERIMENTAL

labelled iron as ferrous sulphate + prebiotics in the form of 15 g GOS

Dietary Supplement: ferrous sulphate + 15 g GOS

ferrous fumarate + Vitamin C

EXPERIMENTAL

labelled iron as ferrous fumarate + Vitamin C

Dietary Supplement: ferrous fumarate + Vitamin C

ferric pyrophosphate + 15 g GOS

EXPERIMENTAL

labelled iron as ferric pyrophosphate + prebiotics in the form of 15 g GOS

Dietary Supplement: ferric pyrophosphate + 15 g GOS

ferrous fumarate + 7 g GOS + Vitamin C

EXPERIMENTAL

labelled iron as ferrous fumarate + prebiotics in the form of 7 g GOS + Vitamin C

Dietary Supplement: ferrous fumarate + 7 g GOS + Vitamin C

Interventions

ferrous fumarateDIETARY_SUPPLEMENT

nutritional iron (14 mg) supplement in form of ferrous fumarate

ferrous fumarate
ferrous sulphateDIETARY_SUPPLEMENT

nutritional iron (14 mg) supplement in form of ferrous sulphate

ferrous sulphate
ferric pyrophosphateDIETARY_SUPPLEMENT

nutritional iron (14 mg) supplement in form of ferric pyrophosphate

ferric pyrophosphate

nutritional iron (14 mg) supplement in form of ferrous fumarate with addition of prebiotics (3.5 g GOS)

ferrous fumarate + 3.5 g GOS
ferrous fumarate + 7 g GOSDIETARY_SUPPLEMENT

nutritional iron (14 mg) supplement in form of ferrous fumarate with addition of prebiotics (7 g GOS)

ferrous fumarate + 7 g GOS
ferrous sulphate + 15 g GOSDIETARY_SUPPLEMENT

nutritional iron (14 mg) supplement in form of ferrous sulphate with addition of prebiotics (15 g GOS)

ferrous sulphate + 15 g GOS

nutritional iron (14 mg) supplement in form of ferrous fumarate with addition of Vitamin C

ferrous fumarate + Vitamin C

nutritional iron (14 mg) supplement in form of ferric pyrophosphate with addition of prebiotics (15 g GOS)

ferric pyrophosphate + 15 g GOS

nutritional iron (14 mg) supplement in form of ferrous fumarate with addition of prebiotics (7 g GOS) and Vitamin C

ferrous fumarate + 7 g GOS + Vitamin C

Eligibility Criteria

Age18 Years - 45 Years
Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsOnly female participants are being studied
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Female, 18 to 45 years old
  • SF levels \<30 µg/L
  • Normal body Mass Index (18.5-24.9 kg/m2)
  • Body weight \<70 kg
  • Signed informed consent

You may not qualify if:

  • Severe anaemia (Hb \< 80 g/L)
  • Elevated CRP \>10.0 mg/L
  • Any metabolic, gastrointestinal kidney or chronic disease such as diabetes, renal failure, hepatic dysfunction, hepatitis, hypertension, cancer or cardiovascular diseases (according to the participants own statement)
  • Continuous/long-term use of medication during the whole studies (except for contraceptives)
  • Consumption of mineral and vitamin supplements within 2 weeks prior to 1st supplement administration, including pre- and-or probiotics supplements (excluding foods and beverages with life cultures such as yoghurt, raw milk cheese and kombucha)
  • Blood transfusion, blood donation or significant blood loss (accident, surgery) over the past 4 months
  • Difficulties with blood sampling
  • Use of antibiotics over the past month
  • Known hypersensitivity to iron supplements in the given amount, GOS, or lactose
  • Women who are pregnant or breast feeding
  • Women who intend become pregnant during the course of the study
  • Lack of safe contraception, defined as: Female participants of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, inject-able, or implantable contraceptives, or intrauterine contraceptive devices, or who are not using any other method considered sufficiently reliable by the investigator in individual cases
  • Known or suspected non-compliance, drug or alcohol (more than 2 drinks/day) abuse -
  • Smokers (\> 1 cigarette per week)
  • Inability to follow the procedures of the study, e.g. due to language problems, self-- reported psychological disorders, etc. of the participant
  • +1 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Human Nutrition Laboratory, ETH Zurich

Zurich, 8092, Switzerland

Location

Related Publications (1)

  • Jeroense FMD, Zeder C, Zimmermann MB, Herter-Aeberli I. Acute Consumption of Prebiotic Galacto-Oligosaccharides Increases Iron Absorption from Ferrous Fumarate, but not from Ferrous Sulfate and Ferric Pyrophosphate: Stable Iron Isotope Studies in Iron-Depleted Young Women. J Nutr. 2020 Sep 1;150(9):2391-2397. doi: 10.1093/jn/nxaa199.

MeSH Terms

Conditions

Anemia, Iron-Deficiency

Interventions

ferrous fumarateferrous sulfateferric pyrophosphateAscorbic Acid

Condition Hierarchy (Ancestors)

Anemia, HypochromicAnemiaHematologic DiseasesHemic and Lymphatic DiseasesIron DeficienciesIron Metabolism DisordersMetabolic DiseasesNutritional and Metabolic Diseases

Intervention Hierarchy (Ancestors)

Sugar AcidsAcids, AcyclicCarboxylic AcidsOrganic ChemicalsHydroxy AcidsCarbohydrates

Study Officials

  • Isabelle Herter-Aeberli, Dr.

    University of Zurich

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
PREVENTION
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
PhD

Study Record Dates

First Submitted

November 30, 2018

First Posted

December 3, 2018

Study Start

April 1, 2019

Primary Completion

June 11, 2019

Study Completion

June 11, 2019

Last Updated

July 25, 2019

Record last verified: 2019-07

Data Sharing

IPD Sharing
Will not share

Locations